These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21170920)

  • 21. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.
    Levy C; Angulo P
    Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216
    [No Abstract]   [Full Text] [Related]  

  • 22. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
    Lindor K
    N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600
    [No Abstract]   [Full Text] [Related]  

  • 23. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary biliary cirrhosis.
    Gong Y; Christensen E; Gluud C
    N Engl J Med; 2005 Dec; 353(25):2719-20; author reply 2719-20. PubMed ID: 16379089
    [No Abstract]   [Full Text] [Related]  

  • 25. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Walker LJ; Newton J; Jones DE; Bassendine MF
    Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy.
    Zukowski TH; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1998 Jun; 93(6):958-61. PubMed ID: 9647028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical studies with silymarin: fibrosis progression is the end point.
    Schuppan D; Hahn EG
    Hepatology; 2001 Feb; 33(2):483-4. PubMed ID: 11172360
    [No Abstract]   [Full Text] [Related]  

  • 31. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis.
    Poupon R; Chrétien Y; Chazouillères O; Poupon RE
    J Hepatol; 2005 Mar; 42(3):418-9. PubMed ID: 15710226
    [No Abstract]   [Full Text] [Related]  

  • 32. Estimation of linear mixed models with a mixture of distribution for the random effects.
    Proust C; Jacqmin-Gadda H
    Comput Methods Programs Biomed; 2005 May; 78(2):165-73. PubMed ID: 15848271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marginalized random effects models for multivariate longitudinal binary data.
    Lee K; Joo Y; Yoo JK; Lee J
    Stat Med; 2009 Apr; 28(8):1284-300. PubMed ID: 19156673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.
    Degott C; Zafrani ES; Callard P; Balkau B; Poupon RE; Poupon R
    Hepatology; 1999 Apr; 29(4):1007-12. PubMed ID: 10094939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients and patience: the pitfalls of primary biliary cirrhosis trials.
    Mayo MJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):552-3. PubMed ID: 16327817
    [No Abstract]   [Full Text] [Related]  

  • 36. Ursodeoxycholic acid: a second look. Primary biliary cirrhosis: dashed hopes.
    Prescrire Int; 2002 Jun; 11(59):67-9. PubMed ID: 12068838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes.
    Talwalkar JA; Gossard AA
    Hepatology; 2008 Apr; 47(4):1428. PubMed ID: 18366110
    [No Abstract]   [Full Text] [Related]  

  • 39. Methotrexate for treatment of primary biliary cirrhosis.
    Bonis PA; Kaplan M
    Hepatology; 2006 Mar; 43(3):632; author reply 632-3. PubMed ID: 16496314
    [No Abstract]   [Full Text] [Related]  

  • 40. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis.
    Dimoulios P; Kolios G; Notas G; Matrella E; Xidakis C; Koulentaki M; Tsagarakis N; Kouroumalis A; Kouroumalis E
    Aliment Pharmacol Ther; 2005 Feb; 21(3):227-34. PubMed ID: 15691296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.